nach oben

Urolithiasis

Erschienen in:

01.02.2016 | Invited Review

Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

verfasst von: Ammon B. Peck, Benjamin K. Canales, Cuong Q. Nguyen

Erschienen in: Urolithiasis | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Renal urolithiasis is a pathological condition common to a multitude of genetic, physiological and nutritional disorders, ranging from general hyperoxaluria to obesity. The concept of quickly dissolving renal uroliths via chemolysis, especially calcium-oxalate kidney stones, has long been a clinical goal, but yet to be achieved. Over the past 25 years, there has been a serious effort to examine the prospects of using plant and microbial oxalate-degrading enzymes known to catabolize oxalic acid and oxalate salts. While evidence is emerging that bacterial probiotics can reduce recurrent calcium-oxalate kidney stone disease by lowering systemic hyperoxaluria, the possible use of free oxalate-degrading enzyme therapy remains a challenge with several hurdles to overcome before reaching clinical practice.

Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369(7):649–658CrossRefPubMed

Svedruzic D, Jonsson S, Toyota CG, Reinhardt LA, Ricagno S, Lindqvist Y, Richards NG (2005) The enzymes of oxalate metabolism: unexpected structures and mechanisms. Arch Biochem Biophys 433(1):176–192CrossRefPubMed

Williams HE, Wandzilak TR (1989) Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol 141(3 Pt 2):742–749PubMed

Rodby RA, Tyszka TS, Williams JW (1991) Reversal of cardiac dysfunction secondary to type 1 primary hyperoxaluria after combined liver-kidney transplantation. Am J Med 90(4):498–504CrossRefPubMed

Menon M, Mahle CJ (1982) Oxalate metabolism and renal calculi. J Urol 127(1):148–151PubMed

Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1993) A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328(12):833–838CrossRefPubMed

Lindsjo M, Danielson BG, Fellstrom B, Ljunghall S (1989) Intestinal oxalate and calcium absorption in recurrent renal stone formers and healthy subjects. Scand J Urol Nephrol 23(1):55–59PubMed

Bulgin MS (1988) Losses related to the ingestion of lincomycin-medicated feed in a range sheep flock. J Am Vet Med Assoc 192(8):1083–1086PubMed

Costello JF, Smith M, Stolarski C, Sadovnic MJ (1992) Extrarenal clearance of oxalate increases with progression of renal failure in the rat. J Am Soc Nephrol 3(5):1098–1104PubMed

10.

Camici M, Balestri PL, Lupetti S, Colizzi V, Falcone G (1982) Urinary excretion of oxalate in renal failure. Nephron 30(3):269–270CrossRefPubMed

11.

Matthews LA, Doershuk CF, Stern RC, Resnick MI (1996) Urolithiasis and cystic fibrosis. J Urol 155(5):1563–1564CrossRefPubMed

12.

Strandvik B, Hjelte L (1993) Nephrolithiasis in cystic fibrosis. Acta Paediatr 82(3):306–307CrossRefPubMed

13.

Katz SM, Krueger LJ, Falkner B (1988) Microscopic nephrocalcinosis in cystic fibrosis. N Engl J Med 319(5):263–266CrossRefPubMed

14.

Hoppe B, Hesse A, Bromme S, Rietschel E, Michalk D (1998) Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis? Pediatr Nephrol 12(4):275–279CrossRefPubMed

15.

Hylander E, Jarnum S, Jensen HJ, Thale M (1978) Enteric hyperoxaluria: dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease. Scand J Gastroenterol 13(5):577–588CrossRefPubMed

16.

Lindsjo M, Danielson BG, Fellstrom B, Lithell H, Ljunghall S (1989) Intestinal absorption of oxalate and calcium in patients with jejunoileal bypass. Scand J Urol Nephrol 23(4):283–289CrossRefPubMed

17.

Stauffer JQ, Humphreys MH (1972) Hyperoxaluria with intestinal disease. N Engl J Med 287(8):412PubMed

18.

Worcester EM, Fellner SK, Nakagawa Y, Coe FL (1994) Effect of renal transplantation on serum oxalate and urinary oxalate excretion. Nephron 67(4):414–418CrossRefPubMed

19.

Dobbins JW, Binder HJ (1977) Importance of the colon in enteric hyperoxaluria. N Engl J Med 296(6):298–301CrossRefPubMed

20.

Allison MJ, Cook HM (1981) Oxalate degradation by microbes of the large bowel of herbivores: the effect of dietary oxalate. Science 212(4495):675–676CrossRefPubMed

21.

Miller AW, Dearing D (2013) The metabolic and ecological interactions of oxalate-degrading bacteria in the Mammalian gut. Pathogens 2(4):636–652PubMedCentralCrossRefPubMed

22.

McDonald GB, Earnest DL, Admirand WH (1977) Hyperoxaluria correlates with fat malabsorption in patients with sprue. Gut 18(7):561–566PubMedCentralCrossRefPubMed

23.

Hatch M, Freel RW, Vaziri ND (1994) Mechanisms of oxalate absorption and secretion across the rabbit distal colon. Pflugers Arch 426(1–2):101–109CrossRefPubMed

24.

Hatch M (1993) Oxalate status in stone-formers. Two distinct hyperoxaluric entities. Urol Res 21(1):55–59CrossRefPubMed

25.

Allison MJ, Cook HM, Milne DB, Gallagher S, Clayman RV (1986) Oxalate degradation by gastrointestinal bacteria from humans. J Nutr 116(3):455–460PubMed

26.

Hatch M (2014) Intestinal adaptations in chronic kidney disease and the influence of gastric bypass surgery. Exp Physiol 99(9):1163–1167PubMedCentralCrossRefPubMed

27.

Kumar R, Ghoshal UC, Singh G, Mittal RD (2004) Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation. J Gastroenterol Hepatol 19(12):1403–1409CrossRefPubMed

28.

Goldfarb DS (2003) Increasing prevalence of kidney stones in the United States. Kidney Int 63(5):1951–1952CrossRefPubMed

29.

Scales CD Jr, Smith AC, Hanley JM, Saigal CS (2012) Prevalence of kidney stones in the United States. Eur Urol 62(1):160–165PubMedCentralCrossRefPubMed

30.

Schissel BL, Johnson BK (2011) Renal stones: evolving epidemiology and management. Pediatr Emerg Care 27(7):676–681CrossRefPubMed

31.

Bihl G, Meyers A (2001) Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet 358(9282):651–656CrossRefPubMed

32.

Khan SR, Hackett RL (1985) Calcium oxalate urolithiasis in the rat: is it a model for human stone disease? A review of recent literature. Scan Electron Microsc (Pt 2):759–774

33.

Khan SR (1997) Animal models of kidney stone formation: an analysis. World J Urol 15(4):236–243CrossRefPubMed

34.

de Bruijn WC, Boeve ER, van Run PR, van Miert PP, de Water R, Romijn JC, Verkoelen CF, Cao LC, Schroder FH (1995) Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? Scanning Microsc 9(1):103–114

35.

Argenzio RA, Liacos JA, Allison MJ (1988) Intestinal oxalate-degrading bacteria reduce oxalate absorption and toxicity in guinea pigs. J Nutr 118(6):787–792PubMed

36.

Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB (2001) Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol 166(4):1487–1491CrossRefPubMed

37.

Cornelius JG, Peck AB (2004) Colonization of the neonatal rat intestinal tract from environmental exposure to the anaerobic bacterium Oxalobacter formigenes. J Med Microbiol 53(Pt 3):249–254CrossRefPubMed

38.

Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB (1999) Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 10(Suppl 14):S334–S340PubMed

39.

Allison MJ, Dawson KA, Mayberry WR, Foss JG (1985) Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141(1):1–7CrossRefPubMed

40.

Allison MJ, MacGregor B, Sharp R, Stahl DA (2001) Genus Oxalobacter vol II. Bergey’s Manual of Systematic Bacteriology. Springer-Verlag, New York

41.

Sidhu H, Enatska L, Ogden S, Williams WN, Allison MJ, Peck AB (1997) Evaluating children in the Ukraine for colonization with the intestinal bacterium Oxalobacter formigenes, using a polymerase chain reaction-based detection system. Mol Diagn 2(2):89–97CrossRefPubMed

42.

Dawson KA, Allison MJ, Hartman PA (1980) Isolation and some characteristics of anaerobic oxalate-degrading bacteria from the rumen. Appl Environ Microbiol 40(4):833–839PubMedCentralPubMed

43.

Daniel SL, Hartman PA, Allison MJ (1987) Microbial degradation of oxalate in the gastrointestinal tracts of rats. Appl Environ Microbiol 53(8):1793–1797PubMedCentralPubMed

44.

Smith RL, Oremland RS (1983) Anaerobic oxalate degradation: widespread natural occurrence in aquatic sediments. Appl Environ Microbiol 46(1):106–113PubMedCentralPubMed

45.

Barnett C, Nazzal L, Goldfarb DS, Blaser MJ (2015) The presence of Oxalobacter formigenes in the microbiome of healthy young adults. J Urol. doi:10.1016/j.juro.2015.08.070 PubMed

46.

Sidhu H, Hoppe B, Hesse A, Tenbrock K, Bromme S, Rietschel E, Peck AB (1998) Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 352(9133):1026–1029CrossRefPubMed

47.

Nathanson S, Frere F, Tassin E, Foucaud P (2003) Urolithiasis in cystic fibrosis. Arch Pediatr 10(9):794–796CrossRefPubMed

48.

Bohles H, Michalk D (1982) Is there a risk for kidney stone formation in cystic fibrosis? Helv Paediatr Acta 37(3):267–272PubMed

49.

Sidhu H, Allison M, Peck AB (1997) Identification and classification of Oxalobacter formigenes strains by using oligonucleotide probes and primers. J Clin Microbiol 35(2):350–353PubMedCentralPubMed

50.

Binder HJ (1974) Intestinal oxalate absorption. Gastroenterology 67(3):441–446PubMed

51.

Moller T, Muller G, Schutte W, Rogos R, Schneider W (1987) Oxalic acid resorption in patients with resection of the small intestine, jejunoileal bypass, Crohn disease and chronic pancreatitis. Dtsch Z Verdau Stoffwechselkr 47(3):113–118PubMed

52.

Caudarella R, Rizzoli E, Pironi L, Malavolta N, Martelli G, Poggioli G, Gozzetti G, Miglioli M (1993) Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc 7(1):371–379 (discussion 379–380)

53.

McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B (2002) Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 89(9):835–841CrossRefPubMed

54.

Trinchieri A, Lizzano R, Castelnuovo C, Zanetti G, Pisani E (2002) Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease. Arch Ital Urol Androl 74(2):61–64PubMed

55.

Worcester EM (2002) Stones from bowel disease. Endocrinol Metab Clin N Am 31(4):979–999CrossRef

56.

Canales BK, Hatch M (2014) Kidney stone incidence and metabolic urinary changes after modern bariatric surgery: review of clinical studies, experimental models, and prevention strategies. Surg Obes Relat Dis 10(4):734–742PubMedCentralCrossRefPubMed

57.

Jairath A, Parekh N, Otano N, Mishra S, Ganpule A, Sabnis R, Desai M (2015) Oxalobacter formigenes: opening the door to probiotic therapy for the treatment of hyperoxaluria. Scand J Urol 49(4):334–337PubMed

58.

Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschenes G, Unwin R, Milliner D (2011) Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 26(11):3609–3615CrossRefPubMed

59.

Mogna L, Pane M, Nicola S, Raiteri E (2014) Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? J Clin Gastroenterol 48(Suppl 1):S91–S95CrossRefPubMed

60.

Sinha M, Prabhu K, Venkatesh P, Krishnamoorthy V (2013) Results of urinary dissolution therapy for radiolucent calculi. Int Braz J Urol 39(1):103–107CrossRefPubMed

61.

Thalji NK, Richards NG, Peck AB, Canales BK (2011) Enzymatic dissolution of calcium and struvite crystals: in vitro evaluation of biochemical requirements. Urology 78(3):721.e713–721.e717

Titel: Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?
verfasst von: Ammon B. Peck
Benjamin K. Canales
Cuong Q. Nguyen
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Urolithiasis / Ausgabe 1/2016
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-015-0845-6

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Abstract

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

How should patients with cystine stone disease be evaluated and treated in the twenty-first century?

The preventive treatment of recurrent stone-formation: how can we improve compliance in the treatment of patients with recurrent stone disease?

The management of patients with enteric hyperoxaluria

Preface

Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease

Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie